Alex Hui

Alex Hui

Auto-generated profile, based on publicly available information

Alex Hui

University of Waterloo School of Optometry and Vision Science

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in Clinical and Experimental Optometry
Verified
Journal Article
Closed access
PDF file
AHAlex Hui
Alex Hui

1 August 2019 in Drug Discovery Today
Verified
Journal Article
Closed access
MMMaria Markoulli
Maria Markoulli
AHAlex Hui
Alex Hui

1 September 2017 in Clinical Ophthalmology
Verified
Journal Article
Open access
PDF file
AHAlex Hui
Alex Hui
MBMagdalena Bajgrowicz-Cieslak
Magdalena Bajgrowicz-Cieslak
CPChau-Minh Phan
Chau-Minh Phan
Lyndon JonesLyndon Jones
Lyndon Jones
The purpose of this study was to investigate the release of the anti-myopia drugs atropine sulfate and pirenzepine dihydrochloride from commercially available soft contact lenses. Standard ultraviolet (UV) absorbance–concentration curves were generated for atropine and pirenzepine. Ten commercially available contact lenses, including four multifocal lenses, were loaded by soaking in atropine or pirenzepine solutions at two different concentrations (10 mg/mL and 1 mg/mL). The release of the drugs into phosphate-buffered saline was determined over the course of 24 hours at 34°C using UV absorbance. Materials with surface charge released the greatest amount of atropine when loaded with either concentration when compared to the other lens types (p<0.05), releasing upward of 1.026±0.035 mg/lens and 0.979±0.024 mg/lens from etafilcon A and ocufilcon A, respectively. There were no significant differences in the amount of atropine or pirenzepine released from the multifocal and non-multifocal lenses made from the same lens materials. Narafilcon A material demonstrated prolonged release of up to 8 hours when loaded with pirenzepine, although the overall dose delivered from the lens into the solution was among the lowest of the materials investigated. The rest of the lenses reached a plateau within 2 hours of release, suggesting that they were unable to sustain drug release into the solution for long periods of time. Given that no single method of myopia control has yet shown itself to be completely effective in preventing myopia progression, a combination of optical and pharmaceutical devices comprising a drug delivering contact lens presents a novel solution that warrants further investigation.

Verified
Journal Article
Open access
PDF file
SQSharon X Qiu
Sharon X Qiu
DFDaddi Fadel
Daddi Fadel
AHAlex Hui
Alex Hui
Scleral lenses (SLs) are large-diameter rigid contact lenses that are a mainstay treatment for eyes with corneal irregularities. In recent years, there has been increased interest in the role of managing dry eye disease (DED) with SLs, as many patients with DED have reported symptomatic relief with SL wear. The role of SLs for DED management when there are associated corneal irregularities is supported by individual case reports and studies. This has prompted practitioners to begin advocating using SLs in DED cases, even in the absence of associated corneal irregularities and other ocular surface diseases (OSDs). There have also been discussions on potentially placing SLs earlier in the treatment hierarchy of DED, where it currently sits at a more advanced level of intervention (Step 3) in the TFOS DEWS II Report. This review will present the currently available, albeit sparse, evidence that supports and suggests this practice, as well as ancillary evidence supporting the purported benefits of SL wear in DED. The advantages of SL wear, such as corneal healing, absence of tear evaporation and contact lens dehydration, and improved visual acuity with associated increased wear comfort, and how this will benefit DED patients will be explored. Conversely, the challenges associated with fitting SLs in DED patients, including increased midday fogging, poor wettability, and subjective patient satisfaction, will also be presented, as well as a discussion on the key considerations for SL fitting in this population. Overall, while more research is needed to support the use of SLs in DED patients without associated corneal irregularities and other forms of OSD, the use of these lenses may prove to have a potentially wider role given their reported ancillary benefits in these populations.

23 November 2024 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
PSPar Shokrollahi
Par Shokrollahi
PGPiyush Garg
Piyush Garg
DWDavid Wulff
David Wulff
AHAlex Hui
Alex Hui
Chau-Minh PhanChau-Minh Phan
Chau-Minh Phan
Lyndon JonesLyndon Jones
Lyndon Jones

25 October 2023 in Clinical and Experimental Optometry
Verified
Journal Article
Closed access
KWKa-Ying Wong
Ka-Ying Wong
CPChau-Minh Phan
Chau-Minh Phan
YCYat-Tin Chan
Yat-Tin Chan
AYAilsa Chui-Ying Yuen
Ailsa Chui-Ying Yuen
HZHuan Zhang
Huan Zhang
MWMan Sau Wong
Man Sau Wong
Traditional Chinese Medicine has a long history in ophthalmology in China. Over 250 kinds of Traditional Chinese Medicine have been recorded in ancient books for the management of eye diseases, which may provide an alternative or supplement to current ocular therapies. However, the core holistic philosophy of Traditional Chinese Medicine that makes it attractive can also hinder its understanding from a scientific perspective - in particular, determining true cause and effect. This review focused on how Traditional Chinese Medicine could be applied to two prevalent ocular diseases, glaucoma, and cataract. The literature on preclinical and clinical studies in both English and Chinese on the use of Traditional Chinese Medicine to treat these two diseases was reviewed. The pharmacological effects, safety profile, and drug-herb interaction of selected herbal formulas were also investigated. Finally, key considerations for conducting future Traditional Chinese Medicine studies are discussed.